Skip to content

Prognostic Prediction Model of Patients With AcUte Stroke undeRgoing EndOvascular TheRApy (AURORA)

Development and Validation for Prognostic Prediction Model of Patients With AcUte Stroke undeRgoing EndOvascular TheRApy (AURORA)

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06009315
Acronym
AURORA
Enrollment
949
Registered
2023-08-24
Start date
2024-02-23
Completion date
2026-12-31
Last updated
2024-08-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Ischemic Stroke

Keywords

Acute ischemic stroke,, Anesthesia, Predictive Model, Endovascular therapy, Deep learning

Brief summary

Stroke is the leading cause of disability-adjusted life years (DALYs) in China, imposing a heavy burden on society and families. Endovascular therapy (EVT) has opened the 2.0 era of acute ischemic stroke (AIS) treatment, but still up to 1/3 of patients have poor neurological prognosis. The results of several studies at home and abroad and by our team indicate that anesthesia method and perioperative management are one of the key factors affecting the neurological prognosis of EVT treatment in AIS patients. Based on machine learning big data analysis methods, a prognostic model for EVT treatment of AIS patients can be established to guide individualized treatment decisions. Current prediction models only include patients' baseline variables, and lack the inclusion of intraoperative (anesthesia management and interventional process) and postoperative (intensive monitoring treatment) variables, which limits the clinical application of prediction tools. We will establish a large prospective cohort database including preoperative, intraoperative, and postoperative variables, integrate heterogeneous information from multiple sources based on artificial intelligence machine learning algorithms, and build prognostic prediction models with better clinical applicability and calibration, with the aim of optimizing perioperative management of endovascular therapy, guiding individualized clinical decision-making, and improving patients' clinical prognosis.

Interventions

None listed

Sponsors

Beijing Tiantan Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

* Age ≥18 years; * NIHSS score ≥4; * Image-confirmed (CTA/MRA/DSA) intracranial large artery occlusion; * ASPECT (anterior circulation) or PC-ASPECT (posterior circulation) score ≥3; * Endovascular treatment including arterial thrombolysis, mechanical thrombolysis, and angioplasty (onset to puncture time is recommended to be less than 8 hours for anterior circulation and less than 12 hours for posterior circulation; those exceeding the time window will be determined by the neurointerventionalist through imaging assessment); * Signed informed consent by the patient or legal representative

Exclusion criteria

* Pre-stroke mRS score \>2; * Intracranial bleeding disorders: cerebral hemorrhage, subarachnoid hemorrhage, etc.; * presence of coagulation disorders, history of systemic bleeding, history of thrombocytopenia or neutropenia; * Renal insufficiency with elevated blood creatinine (greater than 2 times the upper limit of normal); * Presence of severe cardiopulmonary disease that, in the opinion of the investigator, makes participation in this study unsuitable; patients with a life expectancy of less than 3 months or otherwise unable to complete this study; * Contraindication to DSA examination, severe contrast allergy or absolute contraindication to iodine contrast; women of childbearing age who have a negative pregnancy test but refuse to use effective contraception, are pregnant or breast feeding; * Those who are unable to complete the study due to psychiatric disorders, cognitive or mood disorders; * Other patients who, in the opinion of the investigator, are not suitable for enrollment in the study (specify reason).

Design outcomes

Primary

MeasureTime frameDescription
Functional independence at 90 days90±7days after treatmentmodified Rankin Scale of 0-2

Countries

China

Contacts

Primary ContactRuquan Han
ruquan.han@gmail.com8610-59976660
Backup ContactFa Liang
liangfa1001@163.com8610-59976658

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026